Pliant Therapeutics (PLRX) Analyst & Key Data

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts1

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score3.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score5.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$1.17

Median Target+156.41%

$3.00

Potential upside vs current price

DCF Value-76.81%

$0.27

Potential downside vs current price

Current Stock Price

$1.17

Median Target+156.41%

$3.00

Potential upside vs current price

DCF Value-76.81%

$0.27

Potential downside vs current price

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts1

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score3.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score5.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$1.17

Median Target+156.41%

$3.00

Potential upside vs current price

DCF Value-76.81%

$0.27

Potential downside vs current price

Current Stock Price

$1.17

Median Target+156.41%

$3.00

Potential upside vs current price

DCF Value-76.81%

$0.27

Potential downside vs current price

Pliant Therapeutics, Inc.